scholarly journals Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida

2019 ◽  
Vol 22 (10) ◽  
pp. 1202-1207 ◽  
Author(s):  
Maija Reblin ◽  
Solmaz Sahebjam ◽  
Noah C. Peeri ◽  
Yessica C. Martinez ◽  
Zachary Thompson ◽  
...  
Keyword(s):  
Cannabis Use ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Medical Cannabis

scholarly journals Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use

Cancer ◽  
2017 ◽  
Vol 123 (22) ◽  
pp. 4488-4497 ◽  
Author(s):  
Steven A. Pergam ◽  
Maresa C. Woodfield ◽  
Christine M. Lee ◽  
Guang-Shing Cheng ◽  
Kelsey K. Baker ◽  
...  
Keyword(s):  
Cannabis Use ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Recreational Use

Use of medical cannabis in treating anorexia and nausea in elderly cancer patients.

2019 ◽  
Vol 37 (31_suppl) ◽  
pp. 124-124
Author(s):  
Rachel Andrea Nathan ◽  
Charles Tonderai Mupamombe ◽  
Michelle Walter ◽  
Amy Allen Case ◽  
Eric Hansen
Keyword(s):  
Cancer Patients ◽  
Retrospective Chart Review ◽  
The Elderly ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Medical Cannabis ◽  
Care Clinic ◽  
Elderly Cancer Patients ◽  
Used Oil ◽  
Before And After

124 Background: The use of medical cannabis (MC) in cancer symptom treatment has been increasing. Since its legalization is limited to select states, there are few clinical trials that have studied the effectiveness and safety of MC, and even fewer studies in the elderly patient population. Given this, we aimed to evaluate the effects of MC on nausea, appetite, and body mass index (BMI) of elderly cancer patients. Methods: We conducted a retrospective chart review of patients age 65 and older prescribed MC in the year 2018 in an outpatient palliative care clinic at a comprehensive cancer center. Nausea and appetite were measured by numerical rating (0-10) and BMI was recorded with data collected at consecutive clinic visits before and after MC use. Results: Eight-three patients aged 65 and over were included in our analysis. Half of patients were age 65-70, while 12% were age 76 or older. More than half were male (58%) and Caucasian (92%). For patients with anorexia or nausea, 58% had previously used cannabis. For nausea, 58% were prescribed ondansetron, 53% were prescribed prochlorperazine or metoclopramide, and 20% were prescribed olanzapine. For anorexia, 24% were prescribed mirtazapine, 6% were prescribed dronabinol, and 1% were prescribed megestrol. The majority of patients used oil (64%), with one-third using vape (33%) and fewer using pill (17%) and powder (5%). Patients primarily used high THC (50%) or equal THC:CBD (45%) formulations initially, with only 7% using high CBD products. The median nausea and anorexia trended towards improvement, though neither was significant (delta nausea = 0.1, p = 0.81) nor anorexia score (delta anorexia = 0.7, p = 0.69). BMI worsened despite MC use (delta BMI 1.9, p < 0.001). Conclusions: In this study of elderly patients with cancer prescribed MC, more than half had previously used cannabis. Two-thirds of patients with anorexia were using MC first-line for appetite stimulation. The majority of patients used oil, with vape next most commonly used, and the vast majority of patients using high THC or equal THC:CBD initially. Use of MC was not associated with a significant improvement in nausea nor anorexia, and BMI significantly decreased despite MC use.

Efficacy of medical cannabis for cancer-related pain in the elderly: A single-center retrospective analysis.

2019 ◽  
Vol 37 (31_suppl) ◽  
pp. 13-13
Author(s):  
Charles Tonderai Mupamombe ◽  
Rachel Andrea Nathan ◽  
Amy Allen Case ◽  
Michelle Walter ◽  
Eric Hansen
Keyword(s):  
Elderly Patients ◽  
Retrospective Chart Review ◽  
The Elderly ◽  
The United States ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Medical Cannabis ◽  
Care Clinic ◽  
Before And After ◽  
Pain In The Elderly

13 Background: Use of medical cannabis (MC) for cancer-related symptoms is growing, yet many prior studies used formulations not available in the United States (US). Clinical data on formulation, dosing and efficacy for formulations available in the US is limited. Furthermore, though interest is growing in the use of MC for elderly patients, data on safety and efficacy in this population is limited. We aimed to assess the clinical characteristics of elderly people using MC, formulations prescribed, and efficacy for cancer-related pain, insomnia and anxiety. Methods: We conducted a retrospective chart review of patients age 65 and older prescribed MC in the year 2018 in an outpatient palliative care clinic at a tertiary comprehensive cancer center. Pain intensity and anxiety were measured by numerical rating (0-10), and insomnia was assessed by self-reported hours of sleep per night, with data collected at consecutive clinic visits before and after MC use. Results: Eighty-three patients aged 65 and over were included in our analysis. Half of patients were age 65-70, while 12% were age 76 or older. Slightly more than half were male (58%), while the majority were Caucasian (92%). For patients with pain, two thirds were already prescribed opioids; 28% were using gabapentin/pregabalin, 22% duloxetine, and 7% nortriptyline/amitriptyline. Two-thirds (65%) reported never using cannabis previously. The most common MC product used was oil (35%), followed by vape (13%), pill (6%) and powder (3%). The most common initial concentrations were equal THC/CBD (41%) and high THC (43%); 8% of patients used high CBD, and 8% used a combination. The median delta pain score did not change with use of MC (delta pain = 0.0, p = 0.72), nor did anxiety (delta anxiety = -0.2, p = 1.00) nor insomnia (delta hours sleep = -0.1, p = 1.000). Conclusions: In this study of elderly patients prescribed MC, the majority of whom were cannabis naïve and already prescribed opioids, most were initially prescribed high THC or 1:1 THC/CBD, with oil and vape the most common formulations used. Use of MC was not associated with changes in pain, anxiety nor insomnia scores.

ASCO-GU 2019: Fortgeschrittenes Nierenzellkarzinom

2019 ◽  
Vol 10 (02) ◽  
pp. 75-76
Author(s):  
Ine Schmale
Keyword(s):  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Washington Dc

Das Armamentarium zur Behandlung des Nierenzellkarzinoms (RCC) hat sich um effektive Therapien erweitert, durch die der Therapiealgorithmus komplett umgestellt werden musste. Prof. Michael B. Atkins vom Georgetown-Lombardi Comprehensive Cancer Center, Washington DC/USA, und Prof. Daniel Y. C. Heng vom Tom Baker Cancer Center, Calgary/Kanada, teilten beim ASCO-GU ihre Einschätzung zur optimalen Behandlung des Nierenzellkarzinoms in der Erst- und Zweitlinientherapie für das Jahr 2019.

Sign in / Sign up

Export Citation Format

Share Document